BACKGROUND: Although antiretroviral treatment (ART)-related adverse drug reactions (ADR) are documented in industrialised countries, there is no pre-existing surveillance system dedicated to ADR monitoring in most African countries. We assessed knowledge towards pharmacovigilance among ART prescribers and available capacity of HIV clinics to conduct ADR monitoring in Abidjan, Côte d'Ivoire. METHODS: A questionnaire was administered to ART prescribers to assess their knowledge towards the occurrence of ADRs. A retrospective ADR survey was also conducted based on a data query of treatment modification/interruptions in three HIV clinics. Clinical monitors went back to medical charts to review and validate the reasons of the treatment modification/interruptions. RESULTS: Of the 81 ART prescribers interviewed, 25 (31%) declared not grading ADRs and 12 (14.8%) declared notifying ADRs to the national regulatory authorities. Among 5252 adult ART-treated patients who attended the participating clinics in 2008, 599 treatment modifications were identified. Reasons for treatment modification/interruptions identified in the electronic database were documented in the medical charts in 554 cases (92.5%), ADR accounting for 273 cases (45.5%). Toxicity related to ART was graded in only 58 cases (21%) in the medical charts. DISCUSSION: This study describes challenges limiting the implementation of reliable pharmacovigilance activities in HIV clinics in Côte d'Ivoire. The lack of knowledge of ART prescribers concerning ADR grading does not support the spontaneous reporting of ADRs. Using treatment modification/interruptions for ADR monitoring appears feasible, but improvements are needed to respond to key questions related to drug toxicities in the context of ART scale-up in Africa.
BACKGROUND: Although antiretroviral treatment (ART)-related adverse drug reactions (ADR) are documented in industrialised countries, there is no pre-existing surveillance system dedicated to ADR monitoring in most African countries. We assessed knowledge towards pharmacovigilance among ART prescribers and available capacity of HIV clinics to conduct ADR monitoring in Abidjan, Côte d'Ivoire. METHODS: A questionnaire was administered to ART prescribers to assess their knowledge towards the occurrence of ADRs. A retrospective ADR survey was also conducted based on a data query of treatment modification/interruptions in three HIV clinics. Clinical monitors went back to medical charts to review and validate the reasons of the treatment modification/interruptions. RESULTS: Of the 81 ART prescribers interviewed, 25 (31%) declared not grading ADRs and 12 (14.8%) declared notifying ADRs to the national regulatory authorities. Among 5252 adult ART-treated patients who attended the participating clinics in 2008, 599 treatment modifications were identified. Reasons for treatment modification/interruptions identified in the electronic database were documented in the medical charts in 554 cases (92.5%), ADR accounting for 273 cases (45.5%). Toxicity related to ART was graded in only 58 cases (21%) in the medical charts. DISCUSSION: This study describes challenges limiting the implementation of reliable pharmacovigilance activities in HIV clinics in Côte d'Ivoire. The lack of knowledge of ART prescribers concerning ADR grading does not support the spontaneous reporting of ADRs. Using treatment modification/interruptions for ADR monitoring appears feasible, but improvements are needed to respond to key questions related to drug toxicities in the context of ART scale-up in Africa.
Authors: Didier K Ekouevi; Eric Balestre; Franck-Olivier Ba-Gomis; Serge Paul Eholie; Moussa Maiga; Clarisse Amani-Bosse; Albert Minga; Eugène Messou; Papa Salif Sow; Charlotte Lewden; Hamar Allassane Traoré; Emmanuel Bissagnene; François Dabis Journal: Trop Med Int Health Date: 2010-06 Impact factor: 2.622
Authors: Eugène Messou; Xavier Anglaret; Julien Duvignac; Eric Konan-N'dri; Eric Komena; Joachim Gnokoro; Sophie Karcher; Anthony Tanoh; Thérèse N'dri-Yoman; Catherine Seyler Journal: AIDS Date: 2010-01-02 Impact factor: 4.177
Authors: Johan van Griensven; Rony Zachariah; Freya Rasschaert; Jules Mugabo; Edi F Atté; Tony Reid Journal: Trans R Soc Trop Med Hyg Date: 2009-09-03 Impact factor: 2.184
Authors: Ushma Mehta; David Durrheim; Aaron Mabuza; Lucille Blumberg; Elizabeth Allen; Karen I Barnes Journal: Drug Saf Date: 2007 Impact factor: 5.606
Authors: Andrew Boulle; Catherine Orrel; Richard Kaplan; Gilles Van Cutsem; Matthew McNally; Katherine Hilderbrand; London Myer; Matthias Egger; David Coetzee; Gary Maartens; Robin Wood Journal: Antivir Ther Date: 2007
Authors: Alexander N O Dodoo; Carole Fogg; Alex Asiimwe; Edmund T Nartey; Augustina Kodua; Ofori Tenkorang; David Ofori-Adjei Journal: Malar J Date: 2009-01-05 Impact factor: 2.979
Authors: Haggar H Ampadu; Jarno Hoekman; Marieke L de Bruin; Shanthi N Pal; Sten Olsson; Daniele Sartori; Hubert G M Leufkens; Alexander N O Dodoo Journal: Drug Saf Date: 2016-04 Impact factor: 5.606
Authors: Taha E Taha; Nonhlanhla Yende-Zuma; Jim Aizire; Tsungai Chipato; Lillian Wambuzi Ogwang; Bonus Makanani; Lameck Chinula; Mandisa M Nyati; Sherika Hanley; Sean S Brummel; Mary Glenn Fowler Journal: PLoS One Date: 2018-12-13 Impact factor: 3.240
Authors: Antoine Jaquet; Franck Garanet; Eric Balestre; Didier K Ekouevi; Jean Claude Azani; René Bognounou; Elias Dah; Jean Charlemagne Kondombo; François Dabis; Joseph Drabo Journal: J Int AIDS Soc Date: 2013-12-18 Impact factor: 5.396
Authors: Reneé de Waal; Karen Cohen; Andrew Boulle; Matthew P Fox; Gary Maartens; Ehimario U Igumbor; Mary-Ann Davies Journal: PLoS One Date: 2018-09-05 Impact factor: 3.240